Osteoporosis due to cancer treatment: pathogenesis and management.
about
Prevention and treatment of bone fragility in cancer patientCancer treatment-related bone disease.Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent mannerAssessment of fracture risk in women with breast cancer using current vs emerging guidelines.Bone health issues in breast cancer survivors: a Medicare Current Beneficiary Survey (MCBS) study.Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients.Adjuvant Endocrine Therapy in Early Postmenopausal Breast CancerMedication-induced osteoporosis: screening and treatment strategiesGoserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal womenThe science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsNCCN Task Force Report: Bone Health in Cancer Care.The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative reviewChanges in bone density after cancer treatment in patients with cervical and endometrial cancer.The use of bisphosphonates in patients with breast cancer.Diseases affecting bone quality: beyond osteoporosis.Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer PatientsEffect of neoadjuvant chemotherapy on the serum levels of bone turnover markers in women with early-stage breast cancerAssociation of muscle strength and bone mineral density in adult survivors of childhood acute lymphoblastic leukemia.Fracture risk in men with prostate cancer: a population-based study.Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature reviewFracture risk in women with breast cancer: a population-based study.Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.Potential Effects of Phytoestrogen Genistein in Modulating Acute Methotrexate Chemotherapy-Induced Osteoclastogenesis and Bone Damage in Rats.Bisphosphonates and bone metastases: current status and future directions.New therapeutic agents for the treatment of bone diseases.Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcomaCathepsin L targeting in cancer treatment.Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection.Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.Efficacy of the Survivor Health and Resilience Education (SHARE) program to improve bone health behaviors among adolescent survivors of childhood cancer.Aromatase inhibitors and bone loss.Bone mineral density deficits in childhood cancer survivors: Pathophysiology, prevalence, screening, and management.Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.A study to evaluate the cause of bone demineralization in gynecological cancer survivors.The use of bisphosphonates in cancer patients.Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood.Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility.Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer.
P2860
Q26775765-54B2BB9A-0AA0-4442-8A7B-B3E44BD152B3Q30438185-C2F79D12-0A58-4692-B025-167B8C9565FBQ33676779-D77C021A-C101-499D-91BB-10F3EF83AE80Q33723674-5D606C67-D253-4F0B-80B8-1263F9752C87Q33725256-DD7FC9C9-D0D9-48FB-B0AB-EFB2B88EDD5CQ33781670-EAF3D0F6-5417-4EA7-9762-3F2500A254C2Q34096283-ED0E9247-C8B9-468E-999E-28E28AA915CFQ34389358-4E48B8C1-3541-4BCA-88EF-3BC948CEBB7DQ34568109-2E08BC4D-CAAB-4301-99EE-45DE1345B180Q34617864-3639CF98-BD7A-4246-9A25-E168C1B36FA0Q34617936-DDBB31AA-05D4-40B8-929F-CE1CA243F6EEQ34718153-21E1B479-ADBD-4B9A-AC85-6C0E4D79E003Q34784924-C81A90D9-767D-4890-97A6-0470105FD6E9Q35039488-439F6041-81DD-46DD-AA6C-FA18F1FE0474Q35078847-9AE7868E-46B7-4C1E-8D2E-1EA1A91BCF68Q35095543-3BE4DEB7-B358-44EF-AB3C-326D0F2B96CEQ35553550-786D7C3B-7ABC-43E9-8568-38E481406DE0Q35875395-9E130575-FB69-4755-94E2-DDAE628CC4E4Q35876254-D8BA8C17-A4E4-472A-AB06-1C96F44899C1Q35980781-ABBE8DB6-5B0F-493B-9DEB-B7FFBF78F526Q35991921-A20ED1E7-3DD8-490A-86CF-62BCA913710AQ36059331-F3EE607E-8DD8-40E5-BBC0-B57204142975Q36088558-964DE9A5-5B71-4D11-9CF9-E56A2A3CA596Q36118409-D0DBC7FB-ADE8-4396-8CBE-DFFC08C1174BQ36161232-6F1F9F24-549C-43D9-87E0-4C16F64446DDQ36187103-FC515660-F2BE-4E1F-A422-121E31FE4852Q36215768-D82D77FA-342B-462E-A652-D1B1C86DDB09Q36218199-0B9DD88B-F0BA-432F-83E6-8E73FC5C0C66Q36263107-3435D438-E1DB-49CF-B3FC-82DDB5D8AD66Q36388020-C8BE0F92-D927-45CD-B32B-A289D7833C3AQ36431765-4B0ECC27-199F-4BC6-84ED-C7CB0BA7752EQ36598622-912A4E37-2C45-4F29-902F-E168CEAE863AQ36660326-87233116-0833-4ED9-806B-521550F77358Q36723297-C1629436-C994-400B-ACAA-A271BF9E6441Q36804512-C7979094-E4CC-4624-B255-7A601BCADDECQ36846894-ABAA77DC-553D-42DE-984E-4C9A29C0A4C4Q36967138-74947CA8-AF34-47A4-A989-EDCD8A1EE052Q36976210-31BDBE75-4680-44FF-B2BF-20803C693B7BQ37105605-6C453323-289B-4A7B-A346-F0B8E3B762DEQ37195016-AF1C5611-F247-4A20-A15E-8B70DBCBFD57
P2860
Osteoporosis due to cancer treatment: pathogenesis and management.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Osteoporosis due to cancer treatment: pathogenesis and management.
@ast
Osteoporosis due to cancer treatment: pathogenesis and management.
@en
type
label
Osteoporosis due to cancer treatment: pathogenesis and management.
@ast
Osteoporosis due to cancer treatment: pathogenesis and management.
@en
prefLabel
Osteoporosis due to cancer treatment: pathogenesis and management.
@ast
Osteoporosis due to cancer treatment: pathogenesis and management.
@en
P1476
Osteoporosis due to cancer treatment: pathogenesis and management.
@en
P2093
J Pfeilschifter
P304
P356
10.1200/JCO.2000.18.7.1570
P407
P577
2000-04-01T00:00:00Z